MiMedx Group, Inc
MDXG Healthcare Biotechnology
MiMedx Group, Inc’s revenue for fiscal 2025 (year ended December 2025) was $418.6 million, up 20.0% from fiscal 2024. In the quarter to June 2026, revenue fell 34.7%, EPS fell 242.9%, free cash flow fell 174.8% and total debt fell 6.80%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
Follow MDXG
MiMedx Group, Inc (MDXG) EV/Sales
As of 16 October 2026, MiMedx Group, Inc (MDXG) trades at a EV/Sales of 1.5×. Over the past ten years it has ranged from 0.3× (December 2018) to 9.5× (March 2015); the current reading is higher than 19% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.0× | (46.52%) |
| FY2024 | 3.8× | 38.47% |
| FY2023 | 2.7× | 130.56% |
| FY2022 | 1.2× | (54.10%) |
| FY2021 | 2.6× | (31.10%) |
| FY2020 | 3.8× | 39.79% |
| FY2019 | 2.7× | 573.20% |
| FY2018 | 0.4× | (90.47%) |
| FY2017 | 4.2× | 4.30% |
| FY2016 | 4.0× | (21.46%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.3× | 11.18% |
| Mar 2026 | 1.1× | (43.98%) |
| Dec 2025 | 2.0× | (11.91%) |
| Sep 2025 | 2.3× | 4.79% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ANL Adlai Nortye Ltd. Sponsored ADR compare | n/m |
| ANNX Annexon, Inc. compare | n/m |
| AURA Aura Biosciences, Inc. compare | n/m |
| PHAR Pharming Group N.V. Sponsored ADR compare | 1.2× |
| MDXG MiMedx Group, Inc | 1.5× |
| GYRE Gyre Therapeutics, Inc. compare | 4.7× |
| OABI OmniAb, Inc. compare | 14.0× |
| DSGN Design Therapeutics, Inc. compare | 1,934× |
| CADL Candel Therapeutics, Inc. compare | 3,661× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)